The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
The medicine was well tolerated, with no unexpected safety issue
Mehta brings strong leadership experience in biopharmaceuticals, life science research, and diagnostics
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
Subscribe To Our Newsletter & Stay Updated
